BioXcel Therapeutics (NASDAQ:BTAI) and Voyager Therapeutics (NASDAQ:VYGR) Head to Head Analysis

Voyager Therapeutics (NASDAQ:VYGR) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Analyst Recommendations

This is a breakdown of current ratings for Voyager Therapeutics and BioXcel Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1	0	2	1	2.75
BioXcel Therapeutics	1	1	2	0	2.25

Voyager Therapeutics currently has a consensus target price of $16.50, indicating a potential upside of 435.71%. BioXcel Therapeutics has a consensus target price of $11.00, indicating a potential upside of 14,744.80%. Given BioXcel Therapeutics’ higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than Voyager Therapeutics.

Profitability

This table compares Voyager Therapeutics and BioXcel Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-57.92%	-45.00%
BioXcel Therapeutics	-9,549.87%	N/A	-185.82%

Earnings & Valuation

This table compares Voyager Therapeutics and BioXcel Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37 million	4.70	-$119.72 million	($1.80)	-1.71
BioXcel Therapeutics	$640,000.00	3.63	-$69.90 million	($3.79)	-0.02

BioXcel Therapeutics has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by company insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Voyager Therapeutics has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500.

Summary

Voyager Therapeutics beats BioXcel Therapeutics on 10 of the 14 factors compared between the two stocks.

About Voyager Therapeutics

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.